CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference. CCT128930 exhibited marked antiproliferative activity and inhibited the phosphorylation of a range of AKT substrates in multiple tumor cell lines in vitro, consistent with AKT inhibition.
Related Products:
MK-2206 2HCl; Ipatasertib; Triciribine; PHT-427; Capivasertib; Perifosine; AT7867; AT13148; ONC-201; Akti-1/2; SC66; Miltefosine; GSK690693